Xencor (NASDAQ:XNCR) Shares Pass Above 50 Day Moving Average – Here’s Why

Posted by George Bondi on Jul 1st, 2026

Xencor, Inc. (NASDAQ:XNCR – Get Free Report) crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $12.39 and traded as high as $15.62. Xencor shares last traded at $15.60, with a volume of 749,505 shares changing hands.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on XNCR. Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a research report on Wednesday, June 24th. Zacks Research cut Xencor from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 6th. JPMorgan Chase & Co. boosted their price objective on Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a research note on Monday, May 11th. Finally, Wall Street Zen lowered shares of Xencor from a “hold” rating to a “strong sell” rating in a report on Saturday, May 9th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $24.50.

View Our Latest Report on Xencor

Xencor Stock Down 4.5%

The stock has a fifty day simple moving average of $12.50 and a 200 day simple moving average of $12.80. The firm has a market capitalization of $1.14 billion, a P/E ratio of -6.72 and a beta of 0.92.

Xencor (NASDAQ:XNCR – Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.96). Xencor had a negative return on equity of 28.77% and a negative net margin of 177.10%.The business had revenue of $4.52 million during the quarter, compared to the consensus estimate of $27.86 million. During the same period last year, the company earned ($0.66) EPS. The business’s revenue was down 86.2% on a year-over-year basis. Research analysts anticipate that Xencor, Inc. will post -3.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Xencor

A number of institutional investors have recently added to or reduced their stakes in the stock. ADAR1 Capital Management LLC lifted its holdings in shares of Xencor by 66.8% in the first quarter. ADAR1 Capital Management LLC now owns 93,665 shares of the biopharmaceutical company’s stock worth $1,130,000 after buying an additional 37,500 shares in the last quarter. Quantinno Capital Management LP grew its stake in Xencor by 21.1% during the first quarter. Quantinno Capital Management LP now owns 57,077 shares of the biopharmaceutical company’s stock valued at $688,000 after acquiring an additional 9,943 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Xencor by 3.6% during the first quarter. Dimensional Fund Advisors LP now owns 1,294,887 shares of the biopharmaceutical company’s stock valued at $15,613,000 after acquiring an additional 45,599 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Xencor by 2.0% in the 1st quarter. Principal Financial Group Inc. now owns 347,078 shares of the biopharmaceutical company’s stock valued at $4,186,000 after acquiring an additional 6,752 shares during the last quarter. Finally, Fifth Third Bancorp increased its holdings in Xencor by 3,690.2% in the 1st quarter. Fifth Third Bancorp now owns 17,018 shares of the biopharmaceutical company’s stock valued at $205,000 after acquiring an additional 16,569 shares during the last quarter.

About Xencor

(Get Free Report)

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.